GET DAILY SIGNALSWaters Corporation (WAT) Delivers Strong Q3 Beat and Raises Full-Year Outlook, Shares Up +6% Pre-Market
Key Takeaways
- Waters reported third-quarter 2026 revenue of $1.767 billion and adjusted earnings per share (EPS) of $4.10, topping consensus estimates of $1.75 billion and $4.00.
- Adjusted EPS climbed 21% year over year, while GAAP net income declined due to acquisition-related and restructuring costs.
- Organic revenue rose 9% (10% on a constant-currency basis) to $871 million, landing at the high end of management's guidance.
- Waters raised its full-year 2026 outlook, now projecting adjusted EPS of $14.60 to $14.70 and total revenue of $6.479 billion to $6.497 billion.
- The stock traded roughly 6% higher in pre-market activity following the announcement.
- For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages dedicated to Waters Corporation.
- Investors can also explore Trending AI Robots to see automated trading strategies currently gaining traction across the market.
Earnings Context and Why It Matters
Waters Corporation's third-quarter results mark a key milestone following its February 2026 acquisition of Becton, Dickinson's Biosciences and Diagnostics Solutions business, which dramatically expanded the company's scale. The report offers investors a clearer read on how the integration is progressing, how the legacy analytical instruments business is performing, and whether the combined company can sustain margin discipline. With life science tools demand recovering, the quarter also serves as a signal for broader laboratory spending trends. A beat on both revenue and EPS, paired with raised guidance, reinforces confidence that WAT is capturing a durable growth inflection rather than a one-time acquisition boost. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the fiscal quarter ended October 3, 2026, Waters reported total revenue of $1.767 billion, ahead of the roughly $1.75 billion consensus and up sharply from $799.9 million a year earlier, reflecting the acquired businesses. Organic revenue reached $871 million, up 9% as reported and 10% in constant currency, while the acquired Biosciences and Diagnostic Solutions businesses contributed approximately $896 million.
Adjusted EPS came in at $4.10, a 21% increase from $3.40 in the prior-year period and above the $4.00 consensus estimate. On a GAAP basis, however, net income fell to $81 million, or $0.82 per share, from $149 million, or $2.50 per share, a year ago, pressured by acquisition-related, restructuring, and amortization costs. Adjusted operating margin was 30.1%, down 20 basis points year over year on the larger business structure.
Management also raised its 2026 guidance. Full-year adjusted EPS is now expected to be $14.60 to $14.70 (versus a prior $14.45 to $14.65), and total revenue is projected at $6.479 billion to $6.497 billion, a $43 million increase at the midpoint. Organic constant-currency revenue growth for the year is now guided to 9.1% to 9.7%.
Market Reaction and Investor Sentiment
Investors responded favorably to the report. Waters shares closed at $449.53 ahead of the announcement and traded up roughly 6% in pre-market activity after the beat and raised guidance. The positive reaction reflects both the strength of organic growth and the credibility of management's improved full-year outlook. Notably, orders outpaced sales by about $20 million, suggesting demand momentum extends into the fourth quarter. Sentiment was also supported by a rebound in China, where Biosciences posted its first quarter of positive growth in ten quarters. Still, some caution remains around the GAAP profit decline and heavier integration spending, which tempered operating cash flow in the period.
Forward Outlook and Key Factors to Monitor
Looking ahead, Waters guided fourth-quarter 2026 revenue of $1.801 billion to $1.819 billion and adjusted EPS of $4.58 to $4.68, implying double-digit growth in both organic and acquired businesses on a days-adjusted basis. Investors will be watching whether this acceleration materializes and whether the momentum carries into 2027.
Several catalysts are worth monitoring. First, the integration of the acquired Biosciences and Diagnostics Solutions business remains central, with management expecting to deliver over $50 million in revenue synergies in 2026 and citing an earlier-than-expected $200 million in run-rate cost synergies. Second, new product launches, including the FACSDiscover A7 flow cytometer and BACTEC FXI culture system, could drive instrument growth in the coming quarters.
Broader demand signals also matter. Continued strength in China, pharmaceutical reshoring, semiconductor and data center testing, and artificial intelligence-driven lab workflows are key growth vectors. At the same time, cost trends, margin progression, and cash-flow recovery during the integration will be closely watched, particularly given the near-term decline in operating cash flow versus the prior year. From what I see, this is important because it shows the company is executing well on multiple fronts.
Using AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating earnings beats like this one. The tool helps me quickly filter for stocks showing similar technical patterns, fundamentals, and AI-driven signals, which adds useful context when deciding whether to dig deeper into a name like WAT. It has become a regular part of how I scan for ideas without spending hours on manual work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
WAT in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 27, 2026
WAT broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 38 similar instances where the stock broke above the upper band. In 25 of the 38 cases the stock fell afterwards. This puts the odds of success at 66%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for WAT moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 21 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 62%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 70 cases where WAT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 63%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where WAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on WAT as a result. In 60 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for WAT just turned positive on October 21, 2026. Looking at past instances where WAT's MACD turned positive, the stock continued to rise in 28 of 45 cases over the following month. The odds of a continued upward trend are 62%.
Following a +2.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where WAT advanced for three days, in 179 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 118 of 207 cases where WAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. WAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.907) is normal, around the industry mean (65.876). WAT has a moderately high P/E Ratio (112.947) as compared to the industry average of (3.542). Projected Growth (PEG Ratio) (1.649) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (6.752) is also within normal values, averaging (9.775).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of analytical technologies: liquid chromatography, mass spectrometry, and thermal analysis
Industry MedicalSpecialties
Advertisement